AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39375728 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiveCBT (8-week CBT intervention primed with 30 min of moderate-intensity aerobic exercise)
Number of subjects: 40
Study 39375728 — intervention group
Group type: COMPARATOR
Intervention: CalmCBT (8-week CBT intervention while resting for 30 min before CBT)
Number of subjects: 40
Study 39375728 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiveCBT and CalmCBT
Number of subjects: 40
Study 39375781 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal high-intensity interval training (HIIT)
Number of subjects: 162
Study 39375781 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 162
Study 39375781 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 162
Study 39375781 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal HIIT and MICT
Number of subjects: 162
Study 39375869 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/linagliptin fixed-dose combination (FDC [AJU-A51]) 10/5 mg/day (n=117)
Number of subjects: 235
Study 39375869 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin 5 mg plus placebo (n=118)
Number of subjects: 235
Study 39375952 — intervention group
Group type: EXPERIMENTAL
Intervention: ABL001/CTX-009 (10 mg/kg every other week)
Number of subjects: 30
Study 39375952 — intervention group
Group type: EXPERIMENTAL
Intervention: ABL001/CTX-009 (15 mg/kg every three weeks)
Number of subjects: 30
Study 39375952 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based dosing
Number of subjects: 30
Study 39375952 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dosing
Number of subjects: 30
Study 39376152 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP! Rx (exercise and monthly brain health education)
Number of subjects: 219
Study 39376152 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control group
Number of subjects: 219
Study 39376156 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib plus obinutuzumab (ZO)
Number of subjects: 0
Study 39376156 — intervention group
Group type: COMPARATOR
Intervention: Obinutuzumab (O)
Number of subjects: 0
Study 39376771 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2.0% infusion
Number of subjects: 40
Study 39376771 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.9% infusion
Number of subjects: 40
Study 39376791 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic fluids (NaCl <130 mmol/L)
Number of subjects: 420
Study 39376791 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic fluids (NaCl = 130-154 mmol/L)
Number of subjects: 420
Study 39376864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethos OART platform delivering multi-site pulsed hypofractionated radiotherapy (40 Gy in 5 fractions) in combination with standard of care (SOC) chemoimmunotherapy.
Number of subjects: 1
Study 39377069 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-CDS
Number of subjects: 20
Study 39377069 — intervention group
Group type: COMPARATOR
Intervention: EUS-HGS
Number of subjects: 20
Study 39377148 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor administered via nasogastric tube
Number of subjects: 20
Study 39377148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor in resuscitated patients
Number of subjects: 20
Study 39377148 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-C124910XX in resuscitated patients
Number of subjects: 20
Study 39377148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor in semi-urgent CABG patients
Number of subjects: 20
Study 39377148 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-C124910XX in semi-urgent CABG patients
Number of subjects: 20
Study 39377226 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 0
Study 39377226 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IgG1 NANP binding magnitude plus serum NANP and N-junction Ig binding magnitude-avidity composite
Number of subjects: 0
Study 39377442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuses with fetal growth restriction (FGR)
Number of subjects: 0
Study 39377442 — intervention group
Group type: COMPARATOR
Intervention: Normally developed fetuses
Number of subjects: 0
Study 39377681 — intervention group
Group type: EXPERIMENTAL
Intervention: Black Bone (BB) MRI sequence
Number of subjects: 47
Study 39377681 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero Echo Time (ZTE) MRI sequence
Number of subjects: 47
Study 39377681 — intervention group
Group type: COMPARATOR
Intervention: Whole-body CT (reference standard)
Number of subjects: 47
Study 39377681 — intervention group
Group type: EXPERIMENTAL
Intervention: ZTE MRI sequence
Number of subjects: 47
Study 39377970 — intervention group
Group type: EXPERIMENTAL
Intervention: trametinib in a redifferentiation trial
Number of subjects: 5
Study 39377970 — intervention group
Group type: COMPARATOR
Intervention: no redifferentiation therapy
Number of subjects: 5
Study 39378042 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg once daily
Number of subjects: 204
Study 39378042 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 204
Study 39378065 — intervention group
Group type: EXPERIMENTAL
Intervention: Calaspargase pegol-mnkl and cobimetinib
Number of subjects: 0
Study 39378066 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered group program (FAME)
Number of subjects: 10
Study 39378079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic acupuncture with 'De Qi' sensation
Number of subjects: 50
Study 39378079 — intervention group
Group type: COMPARATOR
Intervention: Minimum acupuncture stimulation on nonophthalmic acupoints
Number of subjects: 50
Study 39378080 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive messaging group receiving text messages selected by a reinforcement learning algorithm daily
Number of subjects: 168
Study 39378080 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive messaging group
Number of subjects: 168
Study 39378080 — intervention group
Group type: COMPARATOR
Intervention: Random messaging group receiving randomly selected feedback and motivational text messages daily
Number of subjects: 168
Study 39378080 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a weekly mood monitoring message
Number of subjects: 168
Study 39378100 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Positive app
Number of subjects: 646
Study 39378100 — intervention group
Group type: COMPARATOR
Intervention: Follow-up as usual
Number of subjects: 646
Study 39378124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual hypothermic oxygenated machine perfusion (DHOPE)
Number of subjects: 119
Study 39378124 — intervention group
Group type: COMPARATOR
Intervention: Static cold storage (SCS)
Number of subjects: 119
Study 39378124 — intervention group
Group type: EXPERIMENTAL
Intervention: DHOPE
Number of subjects: 119
Study 39378125 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM2029 (n=48)
Number of subjects: 72
Study 39378125 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=24)
Number of subjects: 72
Study 39378234 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbing group (n = 18)
Number of subjects: 54
Study 39378234 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 54
Study 39378237 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing and relaxation technique in antenatal education class
Number of subjects: 0
Study 39378237 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal education class
Number of subjects: 0
Study 39378281 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week loading dose of 300 mg clofazimine once daily
Number of subjects: 12
Study 39378281 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week loading dose regimen
Number of subjects: 12
Study 39378326 — intervention group
Group type: EXPERIMENTAL
Intervention: IM20×3 group (3 standard doses of 20 μg at 0-1-6 months)
Number of subjects: 504
Study 39378326 — intervention group
Group type: EXPERIMENTAL
Intervention: IM20×4 group (4 standard doses of 20 μg at 0-1-2-6 months)
Number of subjects: 504
Study 39378326 — intervention group
Group type: EXPERIMENTAL
Intervention: IM60×4 group (4 triple doses of 60 μg at 0-1-2-6 months)
Number of subjects: 504
Study 39378385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO)
Number of subjects: 0
Study 39378385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (IPI)
Number of subjects: 0
Study 39378385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39378386 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib plus Ramucirumab (arm A)
Number of subjects: 160
Study 39378386 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib alone (arm B)
Number of subjects: 160
Study 39378393 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy
Number of subjects: 281
Study 39378393 — intervention group
Group type: COMPARATOR
Intervention: 27.5 Gy
Number of subjects: 281
Study 39378423 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive manual, robot-assisted, or traditional open surgery
Number of subjects: 0
Study 39378423 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative technologies and treatment pathways
Number of subjects: 0
Study 39378432 — intervention group
Group type: EXPERIMENTAL
Intervention: RehaPlus+ (personalized eHealth program)
Number of subjects: 169
Study 39378432 — intervention group
Group type: COMPARATOR
Intervention: Usual care (conventional physician-assisted outpatient program)
Number of subjects: 169
Study 39378565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab (DCT)
Number of subjects: 201
Study 39378565 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab (PCT)
Number of subjects: 201
Study 39378565 — intervention group
Group type: COMPARATOR
Intervention: Dostarlimab (DCT) and Pembrolizumab (PCT)
Number of subjects: 201
Study 39379314 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent retriever as first line endovascular thrombectomy (EVT) approach
Number of subjects: 435
Study 39379314 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration as first line endovascular thrombectomy (EVT) approach
Number of subjects: 435
Study 39379314 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tenecteplase with aspiration
Number of subjects: 435
Study 39379314 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tenecteplase with stent retriever
Number of subjects: 435
Study 39379314 — intervention group
Group type: COMPARATOR
Intervention: IV alteplase with aspiration
Number of subjects: 435
Study 39379314 — intervention group
Group type: COMPARATOR
Intervention: IV alteplase with stent retriever
Number of subjects: 435
Study 39379327 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliance with the ERAS protocol
Number of subjects: 600
Study 39379327 — intervention group
Group type: COMPARATOR
Intervention: Compliance with the ERAS protocol
Number of subjects: 600
Study 39379403 — intervention group
Group type: EXPERIMENTAL
Intervention: Viltolarsen 80 mg/kg intravenous once weekly for 48 weeks
Number of subjects: 0
Study 39379403 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (external control group-matched for multiple variables)
Number of subjects: 0
Study 39379403 — intervention group
Group type: EXPERIMENTAL
Intervention: Viltolarsen
Number of subjects: 0
Study 39379413 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural mobilization of the sciatic nerve and its branches (posterior tibial nerve, lateral dorsocutaneous, medial and intermediate dorsocutaneous nerves)
Number of subjects: 18
Study 39379462 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI)
Number of subjects: 9
Study 39379540 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral antibiotics (3-day course)
Number of subjects: 54
Study 39379540 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 54
Study 39379569 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 42
Study 39379569 — intervention group
Group type: COMPARATOR
Intervention: BM aspiration and biopsy (BMAB)
Number of subjects: 42
Study 39379672 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified furosemide responsiveness index (mFRI)
Number of subjects: 1013
Study 39379672 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mFRI and urinary injury biomarkers (uNAG or uNGAL)
Number of subjects: 1013
Study 39379672 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporating mFRI and renal biomarkers into clinical model
Number of subjects: 1013
Study 39379705 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasinezumab (delayed start)
Number of subjects: 271
Study 39379705 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasinezumab (early start)
Number of subjects: 271
Study 39379797 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (lactobacillus) with lifestyle modification for 12 weeks
Number of subjects: 50
Study 39379797 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (low-fat diet and lifestyle modification)
Number of subjects: 50
Study 39379838 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pseudomonal PPM co-isolation
Number of subjects: 453
Study 39379838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas co-isolation
Number of subjects: 453
Study 39379845 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT Shyness Program (internet-delivered cognitive-behavioral therapy)
Number of subjects: 0
Study 39379845 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended by a health professional without guidance
Number of subjects: 0
Study 39379845 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended by a health professional, with low-intensity guidance
Number of subjects: 0
Study 39379845 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39379877 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide Attempts Multi-component Intervention Treatment (SAMIT) - 8 sessions of individual psychotherapy combining Dialectical Behaviour Therapy (DBT), Mentalization-Based Therapy (MBT), and Narrative approaches.
Number of subjects: 0
Study 39379877 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual intervention (TAU)
Number of subjects: 0
Study 39379885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-containing eye drop (BTC)
Number of subjects: 158
Study 39379885 — intervention group
Group type: COMPARATOR
Intervention: Commercially available non-lipid eye drops (NLED)
Number of subjects: 158
Study 39379885 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment difference between BTC and NLED
Number of subjects: 158
Study 39379885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular symptoms
Number of subjects: 158
Study 39379931 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazertinib 240 mg/day
Number of subjects: 78
Study 39379942 — intervention group
Group type: EXPERIMENTAL
Intervention: MethyDT test (IColohunter)
Number of subjects: 1194
Study 39379970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (2-month follow-up educational and/or cognitive-behavioural interventions)
Number of subjects: 130
Study 39379970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 130
Study 39379970 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (control)
Number of subjects: 130
Study 39380004 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning software for real-time motion tracking
Number of subjects: 50
Study 39380004 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning detection
Number of subjects: 50
Study 39380004 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical modelling of study data
Number of subjects: 50
Study 39380015 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PI) irrigation
Number of subjects: 96
Study 39380015 — intervention group
Group type: COMPARATOR
Intervention: Standard irrigation (control)
Number of subjects: 96
Study 39380053 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding - a good start together intervention
Number of subjects: 284
Study 39380078 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated NEWS2 calculation using wearable devices (wristband with PPG sensor)
Number of subjects: 210
Study 39380078 — intervention group
Group type: COMPARATOR
Intervention: Conventional NEWS2 calculation using vital parameters measured by medical staff
Number of subjects: 210
Study 39380086 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA) with 400 mg albendazole
Number of subjects: 0
Study 39380152 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 0
Study 39380152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39380195 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume high-intensity interval training (LV-HIIT, <10 min at high intensity)
Number of subjects: 80
Study 39380195 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume high-intensity interval training (HV-HIIT, >10 min at high intensity)
Number of subjects: 80
Study 39380259 — intervention group
Group type: EXPERIMENTAL
Intervention: Satralizumab (subcutaneous administration)
Number of subjects: 154
Study 39380259 — intervention group
Group type: EXPERIMENTAL
Intervention: Satralizumab exposure and body mass index
Number of subjects: 154
Study 39380627 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (TLM) using smartwatches for continuous monitoring of vital parameters
Number of subjects: 108
Study 39380627 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL) group
Number of subjects: 108
Study 39380737 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted excision (VAE) with complete removal of the biopsy target and subsequent cleaning samples.
Number of subjects: 140
Study 39380737 — intervention group
Group type: COMPARATOR
Intervention: Typical sampling biopsy (control group).
Number of subjects: 140
Study 39380911 — intervention group
Group type: EXPERIMENTAL
Intervention: THC-dominant edible cannabis
Number of subjects: 249
Study 39380911 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD-dominant edible cannabis
Number of subjects: 249
Study 39380911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined THC and CBD edible cannabis
Number of subjects: 249
Study 39380954 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific dosimetry for DTC patients receiving radioiodine (RAI) therapy
Number of subjects: 30
Study 39380967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib (400 mg once daily) and capecitabine (1000 mg/m2)
Number of subjects: 78
Study 39381003 — intervention group
Group type: EXPERIMENTAL
Intervention: ID93+GLA-SE vaccination
Number of subjects: 0
Study 39381032 — intervention group
Group type: EXPERIMENTAL
Intervention: TBR for assessing fluoride uptake in PET-active lesions
Number of subjects: 7
Study 39381416 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT) with technology support
Number of subjects: 168
Study 39381416 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT) without technology support
Number of subjects: 168
Study 39381416 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Training (MIT)
Number of subjects: 168
Study 39381416 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT (with and without technology support)
Number of subjects: 168
Study 39381542 — intervention group
Group type: EXPERIMENTAL
Intervention: COHEC programme (cardiac coherence and medical hypnosis sessions, starting 7 days before the procedure)
Number of subjects: 53
Study 39381542 — intervention group
Group type: EXPERIMENTAL
Intervention: COHEC programme (cardiac coherence and medical hypnosis sessions)
Number of subjects: 53
Study 39381591 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Implementation Support (remote coaching and technical assistance, supplemented with in-person visits)
Number of subjects: 14
Study 39381591 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Implementation Support
Number of subjects: 14
Study 39381591 — intervention group
Group type: COMPARATOR
Intervention: Routine Implementation Support
Number of subjects: 14
Study 39381594 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 200
Study 39381594 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 200
Study 39381608 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIDGE intervention plus service-as-usual
Number of subjects: 40
Study 39381608 — intervention group
Group type: COMPARATOR
Intervention: Service-as-usual alone
Number of subjects: 40
Study 39381651 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix (300 mg) twice daily with add-back therapy (estradiol [1 mg] and norethindrone acetate [0.5 mg] once daily)
Number of subjects: 591
Study 39381651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study 39381777 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal sensor-based eHealth intervention during 14 video sessions of cognitive-behavioral therapy (CBT)
Number of subjects: 20
Study 39381816 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + integrated digital psychological intervention
Number of subjects: 420
Study 39381816 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 420
Study 39381850 — intervention group
Group type: EXPERIMENTAL
Intervention: velmanase alfa 1 mg/kg once weekly
Number of subjects: 21
Study 39381863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegunigalsidase alfa 2 mg/kg every 4 weeks for 52 weeks
Number of subjects: 30
Study 39381863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegunigalsidase alfa
Number of subjects: 30
Study 39382077 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator programmes
Number of subjects: 2895
Study 39382077 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2895
Study 39382091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive screening for early detection of BK viraemia or BK viruria
Number of subjects: 2669
Study 39382091 — intervention group
Group type: COMPARATOR
Intervention: Fluoroquinolones
Number of subjects: 2669
Study 39382222 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily screening and pressure-supported SBT
Number of subjects: 797